NCT03441464View on ClinicalTrials.gov

Feasibility of the LUM Imaging System for Detection of Prostate Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 20, 2019

Primary Completion Date

February 11, 2021

Study Completion Date

February 11, 2021

Conditions
Prostate CancerNeoplasm, Residual
Interventions
COMBINATION_PRODUCT

LUM Imaging System

Patients will be injected with one of 3 study doses of LUM015, or have no LUM015 intervention, and resected tissue will be imaged ex vivo with the LUM imaging device.

Trial Locations (1)

10044

Icahn School of Medicine at Mount Sinai, New York

Sponsors

Lead Sponsor

Lumicell, Inc.
All Listed Sponsors
lead

Lumicell, Inc.

INDUSTRY